16.12.2015

$5 million in funding for research into malaria and tuberculosis drug discovery

by: SGC

University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation. The new funding brings the total investment from the Bill & Melinda Gates Foundation to nearly US $12 million since 2012.

04.12.2015

Takeda renews partnership with Structural Genomics Consortium at MaRS Toronto with new investment of $7.5 million

by: SGC

OAKVILLE, ON, Dec. 4, 2015 /CNW/ - Takeda Pharmaceutical Company Limited (Takeda) today announced it has renewed its partnership with the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to patients faster. Takeda has invested an additional CAD$7.5 million, adding to its initial investment in 2012 of CAD$5 million.

18.11.2015

AbbVie renews commitment to Structural Genomics Consortium

by: SGC

MONTREAL, Nov. 18, 2015 /CNW/ - AbbVie today announced its continued commitment to the Structural Genomics Consortium (SGC) by providing a cash sponsorship of CDA$7.5 million towards open access research leading to the discovery of new medicines. Today`s announcement coincides with meetings with Ontario and Quebec-based research leaders and AbbVie global research and development business development professionals to assess continued investment.

GSK864 Inhibitor for mutant isocitrate dehydrogenase

This probe is available from Sigma and Cayman Chemical.

overview
Probe Negative control

 

GSK864

 

GSK990

GlaxoSmithKline has developed GSK864 [1], a potent and selective inhibitor of mutant IDH1, and has made this available as an SGC chemical probe.  GSK864 inhibits IDH1 mutants R132C/R132H/R132G with IC50 values of 9/15/17 nM, respectively, and is moderately selective over wild-type IDH1 and IDH2 mutants/wild-type. Treatment of R132C IDH1 mutant HT-1080 cells for 24 hours with GSK864 results in a dose-dependent reduction of 2-hydroxyglutarate (2-HG), which is not observed with GSK990, a structurally similar compound which is inactive as an IDH1 inhibitor. GSK864 has been shown to be selective in vitro for IDH1 over other classes of proteins (7TMs, ion channels, kinases) and chemoproteomic studies with GSK321, an analog of GSK864, confirm selective binding of IDH1 by this chemical series.  GSK864 has a pharmacokinetic profile suitable for in vivo studies.

Chemoproteomics: the selectivity of GSK864 for IDH1 was illustrated by conducting a chemoproteomics experiment with a closely related analog, GSK321 [1]. GSK321 was functionalized so that it could be immobilized to NHS-activated Sepharose beads which were then incubated with a lysate (protein concentration 5 mg/mL) from HT-1080 cells. The experimental plan included using GSK990 and vehicle as control bait. The proteins were eluted from the beads and then subjected to in-gel digestion and labelling with TMT reagents. LC/MS/MS identified over 300 proteins of which only one, IDH1 had IC50 < 200 nM. 

properties
Probe Negative control

 

GSK864

 

GSK990

Physical and chemical properties for GSK864
Molecular weight560.3
Molecular formulaC30H33FN6O4
MollogP3.162
PSA98.62
No. of chiral centres1
No. of rotatable bonds10
No. of hydrogen bond acceptors8
No. of hydrogen bond donors4
Physical and chemical properties for GSK990 (Negative Control)
Molecular weight429.2
Molecular formulaC23H23N7O2
IUPAC name(7-((1H-imidazol-4-yl)-methyl)-9-((3-methyl-phenylamino)-formyl)-3,7,8-triaza-bicyclo[4.3.0]nona-1(6),8-dien-3-yl)-(1H-pyrrol-2-yl)-methanone
MollogP1.316
PSA85.96
No. of chiral centres0
No. of rotatable bonds7
No. of hydrogen bond acceptors6
No. of hydrogen bond donors3
  • SMILES:
  • GSK864: CC1=CC(NC(C2=NN(CC3=CC=C(F)C=C3)C4=C2CN(C(C5=CC=CN5)=O)C[C@](C(N)=O)4C)=O)=CC(C)=C1OC
  • GSK990: CC1=CC=CC(NC(C2=NN(CC3=CNC=N3)C4=C2CN(C(C5=CC=CN5)=O)CC4)=O)=C1
  • InChI:
  • GSK864: InChI=1S/C30H33FN6O4/c1-18-12-22(13-19(2)26(18)40-4)34-28(38)25-23-15-36(29(39)24-6-5-11-33-24)16-30(3,17-41-32)27(23)37(35-25)14-20-7-9-21(31)10-8-20/h5-13,33H,14-17,32H2,1-4H3,(H,34,38)/t30-/m1/s1
  • GSK990: InChI=1S/C23H23N7O2/c1-15-4-2-5-16(10-15)27-22(31)21-18-13-29(23(32)19-6-3-8-25-19)9-7-20(18)30(28-21)12-17-11-24-14-26-17/h2-6,8,10-11,14,25H,7,9,12-13H2,1H3,(H,24,26)(H,27,31)
  • InChIKey:
  • GSK864: DUCNNEYLFOQFSW-PMERELPUSA-N
  • GSK990: PYCSPHYSYJHUKG-UHFFFAOYSA-N


GSK321
(analog)

Physical and chemical properties for GSK990 (Negative Control)
Molecular weight501.2
Molecular formulaC28H28FN5O3
IUPAC name(7-(4-fluoro-benzyl)-9-((3-(1-hydroxy-ethyl)-phenylamino)-formyl)-5-methyl-3,7,8-triaza-bicyclo[4.3.0]nona-1(6),8-dien-3-yl)-(1H-pyrrol-2-yl)-methanone
MollogP3.285
PSA79.77
No. of chiral centres2
No. of rotatable bonds8
No. of hydrogen bond acceptors6
No. of hydrogen bond donors3
  • SMILES:
  • GSK321: C[C@@H](c1cccc(c1)NC(c1c2CN(C[C@@H](C)c2n(Cc2ccc(cc2)F)n1)C(c1ccc[nH]1)=O)=O)O
  • InChI:
  • GSK321: InChI=1S/C28H28FN5O3/c1-17-14-33(28(37)24-7-4-12-30-24)16-23-25(27(36)31-22-6-3-5-20(13-22)18(2)35)32-34(26(17)23)15-19-8-10-21(29)11-9-19/h3-13,17-18,30,35H,14-16H2,1-2H3,(H,31,36)/t17-,18+/m1/s1
  • InChIKey:
  • GSK321: IVFDDVKCCBDPQZ-MSOLQXFVSA-N
selectivity profile
in vitro potency
cell based assay data
references
  1. UC Okoye-Okafor , B Bartholdy, J Cartier, EN Gao, B Pietrak, etc. (2015) New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nature Chem. Biol. 11: 878–868.
pk properties
co-crystal structures
synthetic schemes
materials and methods
03.09.2015

The Ontario Institute for Cancer Research and the Structural Genomics Consortium develop and give away new drug-like molecule to help crowd-source cancer research.

by: SGC

Through a novel open source approach the molecule has been made freely available to the cancer research community to help discover new therapeutic strategies for cancer patients sooner.

15.07.2015

WDR5 Antagonism-A WINning Approach

by: SGC

WD Repeat domain 5 (WDR5) is a critical part of the human trithorax/COMPASS complexes which are responsible for methylation of lysine 4 on histone 3 (H3K4) via one of several catalytic subunits, Mixed-Lineage Leukemia (MLL), MLL2, MLL3, or MLL4 proteins.

MS023 A chemical probe for Type I PRMTs

This probe is available from Cayman Chemical.

This probe (hydrochloride) is available from Sigma, Tocris and Cayman Chemical .

The negative control (MS094) is available for purchase from Sigma.

overview
Probe Negative control
 

MS023

 

MS094

Protein arginine methyltransferases (PRMTs) play a crucial role in a variety of biological processes [1]. Overexpression of PRMTs has been implicated in various human diseases including cancer [2-4]. To date, nine PRMTs have been identified and they are grouped into three categories: types I, II and III. Type I PRMTs catalyze mono- and asymmetric dimethylation of arginine residues and include PRMT1, 3, 4 (also known as CARM1 (Co-activator-associated arginine methyltransferase 1)), 6 and 8. It has been shown that knocking down the expression of PRMT1 or PRMT6 genes (using siRNA) significantly reduces the growth of bladder and lung cancer cells [5]. Consequently, selective small-molecule inhibitors of PRMTs have been pursued by both academia and pharmaceutical industry as chemical tools for testing biological and therapeutic hypotheses [6,7].

A collaboration between the Icahn School of Medicine at Mount Sinai and the SGC has resulted in MS023 [8], a chemical probe for type I PRMTs, and a structurally similar control compound, MS094. The in vitro and cell-based activity of MS023 is summarized in the table and the Western blots.

(A) MS023 inhibits PRMT1 methyltransferase activity in MCF7 cells. (B) MS094 does not inhibit PRMT1 methyltransferase activity in MCF7 cells. MCF7 cells were treated with MS023 (A) or MS094 (B) at indicated concentrations for 48 h and H4R3me2a levels were determined by Western blot. The graphs represent nonlinear fits of H4R3me2a signal intensities normalized to total histone H4. The results are MEAN ± SEM of two experiments done in triplicate. (C) MS023 inhibits PRMT6 methyltransferase activity in HEK293 cells. HEK293 cells were transfected with FLAG-tagged PRMT6 or its catalytically inactive mutant V86K/D88A (MUT) and treated with MS023 at indicated concentrations for 20 h. H3R2me2a levels were determined by Western blot. The graphs represent nonlinear fits of H3R2me2a signal intensities normalized to total histone H3. The results are MEAN ± SEM of 3 replicates.

properties
Probe Negative control
 

MS023

 

MS094

Physical and chemical properties for MS023
Molecular weight287.2
Molecular formulaC17H25N3O
IUPAC name3-(((2-amino-ethyl)-methyl-amino)-methyl)-4-(4-(1-methyl-ethoxy)-phenyl)-1H-pyrrole
MollogP1.798
PSA42.64
No. of chiral centres0
No. of rotatable bonds7
No. of hydrogen bond acceptors3
No. of hydrogen bond donors3
Physical and chemical properties for MS094 (Negative Control)
Molecular weight288.2
Molecular formulaC17H24N2O2
IUPAC name2-(methyl-((4-(4-(1-methyl-ethoxy)-phenyl)-1H-pyrrol-3-yl)-methyl)-amino)-ethanol
MollogP2.397
PSA38.15
No. of chiral centres0
No. of rotatable bonds7
No. of hydrogen bond acceptors3
No. of hydrogen bond donors2
  • SMILES:
  • MS023: CN(CC1=CNC=C1C2=CC=C(C=C2)OC(C)C)CCN
  • MS094: CN(CC1=CNC=C1C2=CC=C(C=C2)OC(C)C)CCO
  • InChI:
  • MS023: InChI=1S/C17H25N3O/c1-13(2)21-16-6-4-14(5-7-16)17-11-19-10-15(17)12-20(3)9-8-18/h4-7,10-11,13,19H,8-9,12,18H2,1-3H3
  • MS094: InChI=1S/C17H24N2O2/c1-13(2)21-16-6-4-14(5-7-16)17-11-18-10-15(17)12-19(3)8-9-20/h4-7,10-11,13,18,20H,8-9,12H2,1-3H3
  • InChIKey:
  • MS023: FMTVWAGUJRUAKE-UHFFFAOYSA-N
  • MS094: GNAKYUUZAXUXKB-UHFFFAOYSA-N
selectivity profile

MS023 is a potent Type 1 PRMT inhibitor.

Selectivity

Selectivity of MS023 within methyltransferase family

in vitro potency
cell based assay data

Cellular activity

MS023 is a potent inhibitor of H4R3 and H3R2 methylation in cells.  At 50 microM the negative control, MS094, does not affect H4R3 methylation.

references

[1] Bedford M T and Clarke SG (2009) Protein Arginine Methylation in Mammals: Who, What, and Why, Mol. Cell 33, 1-13.

[2] Wei H, Mundade R, Lange KC, et al. (2014) Protein arginine methylation of non-histone proteins and its role in diseases, Cell Cycle 13, 32-41.

[3] KaniskanH Ü, Konze KD, and Jin J. (2015) Selective Inhibitors of Protein Methyltransferases, J. Med. Chem. 58, 1596-1629.

[4] Yang YZ and Bedford MT (2013) Protein arginine methyltransferases and cancer, Nat. Rev. Cancer 13, 37-50.

[5] Yoshimatsu M, Toyokawa G, Hayami S, et al. (2011) Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers, Int. J. Cancer 128, 562-573.

[6] Kaniskan HÜ, Szewczyk MM, Yu Z, et al. (2015) A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl 54, 5166-70.

[7] Mitchell LH, Drew AE, Ribich SA, et al. (2015) Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Med Chem Lett. 6, 655-9.

[8] Eram MS, Shen Y, Szewczyk M, et al. (2015) A Potent, Selective and Cell-active Inhibitor of Human Type I Protein Arginine Methyltransferases, ACS Chemical Biology DOI: 10.1021/acschembio.5b00839. 

pk properties
co-crystal structures

Please wait whilst the interactive viewer is loaded!

Main features

synthetic schemes
materials and methods

GSK591 A chemical probe for PRMT5

This probe is available from Cayman Chemical and Tocris (dihydrochloride).

The control may be requested by clicking here.

overview
Probe Negative control

 

GSK591

 

SGC2096

Protein arginine methyltransferases (PRMTs) play a crucial role in a variety of biological processes [1]. Overexpression of PRMTs has been implicated in various human diseases including cancer [2-4]. To date, nine PRMTs have been identified and they are grouped into three categories: types I, II and III. Type II PRMTs, 5 and 9, catalyze symmetric dimethylation of arginine residues, however, PRMT5 is the predominant enzyme for this process. PRMT5 interacts with a number of binding partners that influence its substrate specificity. In particular, MEP50, a member of the WD40 family of proteins, is required for PRMT5 methyltransferase activity.

PRMT5 is reported to have a role in mantle cell lymphoma (MCL) as evidenced by its upregulation in patient samples [5,6]. Consequently, a chemical probe of PRMT5 would be a very useful tool for testing biological and therapeutic hypotheses. The first chemical probe of PRMT5 was co-developed by Epizyme and GlaxoSmithKline (GSK) [7]. An analog of this compound, EPZ015866/GSK3203591 [8], has been kindly donated to the SGC for distribution as GSK591. In an in vitro biochemical assay, GSK591 potently inhibits the PRMT5/MEP50 complex from methylating (histone) H4 with IC50 = 11 nM. In Z-138 cells, GSK591 inhibits the symmetric arginine methylation of SmD3 with EC50 = 56 nM. Further, GSK591 is selective for PRMT5 (up to 50 micromolar) relative to a panel of methyltransferases. 

A control compound, SGC2096, that is inactive up to 10 micromolar is also available from the SGC.

In addition, a biotinylated inhibitor, SGC3185 is available

Biotinylated inhibitor

SGC3185

In Vitro potency

Radioactivity assay using H4 (1-15) as substrate

properties
Probe Negative control

 

GSK591

 

SGC2096

Physical and chemical properties for GSK591
Molecular weight380.2
Molecular formulaC22H28N4O2
IUPAC name(3-(3-aza-bicyclo[4.4.0]deca-1(10),6,8-trien-3-yl)-2-hydroxy-propylamino)-(2-cyclobutylamino-pyridin-4-yl)-methanone
MollogP2.311
PSA64.84
No. of chiral centres1
No. of rotatable bonds8
No. of hydrogen bond acceptors5
No. of hydrogen bond donors3
Physical and chemical properties for SGC2096
Molecular weight332.2
Molecular formulaC18H28N4O2
IUPAC name(2-cyclobutylamino-pyridin-4-yl)-(2-hydroxy-3-(piperidin-1-yl)-propylamino)-methanone
MollogP1.991
PSA65.18
No. of chiral centres1
No. of rotatable bonds8
No. of hydrogen bond acceptors5
No. of hydrogen bond donors3
  • SMILES:
  • GSK591: O[C@H](CN1CCC2=CC=CC=C2C1)CNC(C3=CC=NC(NC4CCC4)=C3)=O
  • SGC2096: O=C(C1=CC=NC(NC2CCC2)=C1)NC[C@H](O)CN3CCCCC3
  • InChI:
  • GSK591: InChI=1S/C22H28N4O2/c27-20(15-26-11-9-16-4-1-2-5-18(16)14-26)13-24-22(28)17-8-10-23-21(12-17)25-19-6-3-7-19/h1-2,4-5,8,10,12,19-20,27H,3,6-7,9,11,13-15H2,(H,23,25)(H,24,28)/t20-/m0/s1
  • SGC2096: InChI=1S/C18H28N4O2/c23-16(13-22-9-2-1-3-10-22)12-20-18(24)14-7-8-19-17(11-14)21-15-5-4-6-15/h7-8,11,15-16,23H,1-6,9-10,12-13H2,(H,19,21)(H,20,24)/t16-/m0/s1
  • InChIKey:
  • GSK591: TWKYXZSXXXKKJU-FQEVSTJZSA-N
  • SGC2096: DCHQEWPVLGTADW-INIZCTEOSA-N
Biotinylated inhibitor

SGC3185

Physical and chemical properties for GSK3185
Molecular weight854.4
Molecular formulaC42H62N8O9S
IUPAC name6-(5-(2-(2-(2-(2-(3-(3-(4-((3-(3-aza-bicyclo[4.4.0]deca-1(10),6,8-trien-3-yl)-2-hydroxy-propylamino)-formyl)-pyridin-2-ylamino)-azetidin-1-yl)-3-oxo-propoxy)-ethoxy)-ethoxy)-ethoxy)-ethylamino)-5-oxo-pentyl)-7-thia-2,4-diaza-bicyclo[3.3.0]octan-3-one
MollogP1.341
PSA175.1
No. of chiral centres4
No. of rotatable bonds30
No. of hydrogen bond acceptors16
No. of hydrogen bond donors6

SMILES: [H][C@@]12[C@H](CCCCC(NCCOCCOCCOCCOCCC(N3CC(C3)Nc3cc(ccn3)C(NC[C@@H](CN3CCc4ccccc4C3)O)=O)=O)=O)SC[C@]1([H])NC(N2)=O

InChI: InChI=1S/C42H62N8O9S/c51-34(28-49-14-10-30-5-1-2-6-32(30)25-49)24-45-41(54)31-9-12-43-37(23-31)46-33-26-50(27-33)39(53)11-15-56-17-19-58-21-22-59-20-18-57-16-13-44-38(52)8-4-3-7-36-40-35(29-60-36)47-42(55)48-40/h1-2,5-6,9,12,23,33-36,40,51H,3-4,7-8,10-11,13-22,24-29H2,(H,43,46)(H,44,52)(H,45,54)(H2,47,48,55)/t34-,35-,36-,40-/m0/s1

InChIKey: PZIWNLNYZRZJCY-VNLYVSNMSA-N

selectivity profile

in vitro potency
cell based assay data

Dose-dependant decrease in SDMA in Z-138 cells

references

References

  1. Bedford M T and Clarke SG (2009) Protein Arginine Methylation in Mammals: Who, What, and Why, Mol. Cell 33, 1-13.
  2. Wei H, Mundade R, Lange KC, et al. (2014) Protein arginine methylation of non-histone proteins and its role in diseases, Cell Cycle 13, 32-41.
  3. Kaniskan HÜ, Konze KD, and Jin J. (2015) Selective Inhibitors of Protein Methyltransferases, J. Med. Chem. 58, 1596-1629.
  4. Yang YZ and Bedford MT (2013) Protein arginine methyltransferases and cancer, Nat. Rev. Cancer 13, 37-50.
  5. Chung J, Karkhanis V, Tae S, et al. (2013) Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. J Biol Chem 288, 35534-35547.
  6. Pal S, Baiocchi RA, Byrd JC, et al. (2007) Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 26, 3558–3569.
  7. Chan-Penebre E, Kuplast KG, Majer CR, et al. (2015) A selective inhibitor of PRMT with in vivo and in vitro potency in MCL models. Nature Chem Biol. 11, 432-441.
  8. Duncan KW, Rioux N, Boriack-Sjodin PA, et al. (2015) Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Med Chem Lett. DOI: 10.1021/acsmedchemlett.5b00380. 
pk properties
co-crystal structures

Please wait whilst the interactive viewer is loaded!



PDB 5C9Z
Main features

  1. Peptide structure with SAM analog 
  2. GSK591 with Sinefungin 
  3. GSK591 Key interactions 
synthetic schemes
materials and methods

A-196 A selective chemical probe for SUV420H1/H2

This probe is available from Sigma, Cayman Chemical and Tocris.

The control may be requested by clicking here.

overview
Probe Negative control Alternative control

 

 

A-196

 

SGC2043

 

A-197

Histone H4 lysine 20 methylation is emerging as a crucial modification to ensure genomic integrity both in the absence and presence of genotoxic stress [1]. The majority of histone H4 methylation is detected in the lysine 20 (H4K20) and is evolutionarily conserved from yeast to human [2,3]. Each methylation state results in distinct biology: dimethylated H4K20 (H4K20me2) is involved in DNA replication and DNA damage repair, and trimethylated H4K20 (H4K20me3) results in silenced heterochromatic regions [1]. Loss of histone H4 lysine 20 trimethylation (H4K20me3) is characteristic of human cancer and a potential prognostic marker in many types of cancers [4].

SUV420H1 and SUV420H2 are two highly homologous methyltransferases that di- and tri-methylate  'Lys-20' of histone H4. A collaboration between AbbVie and the SGC has resulted in the discovery of A-196 [5], the first potent and selective chemical probe for SUV420H1 and SUV420H2. The in vitro activity of A-196 includes inhibition of SUV420H1 with IC50 = 25 nM and SUV420H2 with IC50 = 144 nM for methylation of H4K20me and greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets. In cell assays, A-196 inhibits the di- and tri-methylation of H4K20me in multiple cell lines with IC50 < 1 µM.

in vitro / biochemical potency

Mechanism of action

properties
Probe Negative control Alternative control

 

 

A-196

 

SGC2043

 

A-197

Physical and chemical properties for A-196
Molecular weight358.1
Molecular formulaC18H16Cl2N4
IUPAC name8,9-dichloro-N-cyclopentyl-5-(pyridin-4-yl)-3,4-diaza-bicyclo[4.4.0]deca-1(10),2,4,6,8-pentaen-2-amine
MollogP5.04
PSA42.6
No. of chiral centres0
No. of rotatable bonds3
No. of hydrogen bond acceptors3
No. of hydrogen bond donors1
Physical and chemical properties for A-197
Molecular weight408.1            
Molecular formulaC19H22Cl2N4O2
IUPAC name(8,9-dichloro-5-cyclopentylamino-3,4-diaza-bicyclo[4.4.0]deca-1(10),2,4,6,8-pentaen-2-yl)-(4-hydroxy-piperidin-1-yl)-methanone
MollogP3.689
PSA65.82
No. of chiral centres0
No. of rotatable bonds4
No. of hydrogen bond acceptors5
No. of hydrogen bond donors2
  • SMILES:
  • A-196: [H]N(C1=NN=C(C2=CC=NC=C2)C3=C1C=C(Cl)C(Cl)=C3)C4CCCC4
  • A-197: C1CCC(C1)Nc1c2cc(c(cc2c(C(N2CCC(CC2)O)=O)nn1)[Cl])[Cl]
  • InChI:
  • A-196:InChI=1S/C18H16Cl2N4/c19-15-9-13-14(10-16(15)20)18(22-12-3-1-2-4-12)24-23-17(13)11-5-7-21-8-6-11/h5-10,12H,1-4H2,(H,22,24)
  • A-197: InChI=1S/C19H22Cl2N4O2/c20-15-9-13-14(10-16(15)21)18(22-11-3-1-2-4-11)24-23-17(13)19(27)25-7-5-12(26)6-8-25/h9-12,26H,1-8H2,(H,22,24)
  • InChIKey:
  • A-196: ABGOSOMRWSYAOB-UHFFFAOYSA-N
  • A-197: NGGSLWXNDXYNJL-UHFFFAOYSA-N
selectivity profile

Selectivity of A-196 is selective against 29 methyltransferases

Selectivity of A-196 against epigenetic reader domains

in vitro potency
cell based assay data

Cell Assay

references

[1] Jorgensen S, Schotta G, Sorenson CS. (2013) Histone H4 Lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Research 41: 2797-806.

[2] Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, et al. (2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 18:1251–1262.

[3] Sanders SL, Portoso M, Mata J, Bahler J, Allshire RC, et al. (2004) Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell; 119:603–614.

[4] Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400.

[5] Bromberg KD, Mitchell TR, Upadhyay AK, Jakob CG, Jhala MA, et al. (2017 Jan 23) The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 

pk properties
co-crystal structures
synthetic schemes
materials and methods

NVS-CECR2-1 A chemical probe for CECR2

This probe is available from Cayman Chemical and Tocris.

overview
Probe Negative control

 

NVS-CECR2-1

 

NVS-CECR2-C

Biology of Probe and Target

NVS-CECR2-1 is a highly potent and selective CECR2 inhibitor that has been developed in collaboration with Novartis. CECR2 (cat eye syndrome chromosome region, candidate 2) gene previously was identified as being in the chromosome 22q11 region, duplicated in the human disorder cat eye syndrome (1). This syndrome is characterized by defects of the eye, heart, anus, kidney, skeleton, face and mental development; however the neural tube develops normally. CECR2 deletion in mice causes neural tube defects including severe exencephaly and perinatal death (2). CECR2 is predominantly expressed in the nervous system and involved in neurulation. Chromatin remodelling complexes play critical roles in development and CECR2 has been shown to be part of the CERF complex with SNF2L forming an ATP-dependent chromatin remodeller (2). CECR2 shows complex alternative splicing, but all variants contain DDT and bromodomain motifs. CECR2 has also been suggested to play a role in DNA damage response by inhibiting γ-H2AX (3).
NVS-CECR2-1 binds to CECR2 with high affinity (IC50 of 47 nM in alpha screen, KD = 80 nM in ITC), and demonstrates no cross reactivity in a BRD panel (48 targets). In the FRAP assay at 0.1 µM NVS-CECR2-1 shows robust activity in cells due to its slow off-rate, but no acute toxicity. No major activity is observed in kinase, protease and receptor panels.
NVS-CECR2-1 is poorly soluble but due to its high potency it may be safely used at low concentrations in cell biology applications. The structurally related NVS-CECR2-C is a suitable control compound that is inactive against CECR2.

Phylogenetic tree of bromodomains and detailed view at CECR2.

Potency Against Target Family

BromodomainKd/nM (ITC)IC50/nM (Alpha Screen)TM Shift °C
CECR2804712.52
BRD4NT>37,0001.73
BRD7NT55001.21
BRD9NT2300NT
(NT=Not Tested)

NVS-CECR2-1 is a highly potent inhibitor for CECR2 with a KD of 80 nM and shows very good potency in FRAP assay at 0.1 µM due to its slow off-rate. Alpha Screen confirmed NVS-CECR2-1 as a potent inhibitor of CECR2 with a IC50 of 47 nM.

Selectivity

NVS-CECR2-1 induced significant ΔTm shifts (12.52 °C). Only weak interactions were observed for BRD4 (1.73 °C) and BRD7 (1.21 °C), however alpha screen did not reveal strong interactions. NVS-CECR2-1 shows no cross reactivity among bromodomains and no significant inhibition of protein kinases, proteases and receptors.

Dosage

Use at concentrations of up to 1 µM in cellular assays. The structurally related NVS-CECR2-C is a suitable control compound that is inactive against CECR2.

Cellular Activity

In a NanoBRETTM assay, CECR2 shows dose-dependent displacement from histone H3.3, with IC50 of 255 nM and the FRAP assay reveals robust inhibition of CECR2 at 0.1µM concentration of NVS-CECR2-1.

properties
Probe

NVS-CECR2-1

Physical and chemical properties
Molecular weight495.68
Molecular formulaC27H37N5O2S
IUPAC nameN-cyclopropyl-2-propylsulfonyl-6-[1-(2,2,6,6-tetramethylpiperidin-4-yl)indol-5-yl]pyrimidin-4-amine
clogP4.5
PSA97.3
No. of chiral centres0
No. of rotatable bonds7
No. of hydrogen bond acceptors6
No. of hydrogen bond donors2
Storagestable as solid in the dark at -20°C. NB making aliquots rather than freeze-thawing is recommended
DissolutionSoluble in DMSO
  • SMILES:
  • NVS-CECR2-1: CC1(CC(CC(C)(N1)C)N2C=CC3=C2C=CC(C4=CC(NC5CC5)=NC(S(=O)(CCC)=O)=N4)=C3)C
  • NVS-CECR2-C: CC1(CC(CC(C)(N1)C)N2C=CC3=C2C=CC(C4=NC(NC5CC5)=CC(S(=O)(CCC)=O)=N4)=C3)C
  • InChI:
  • NVS-CECR2-1: InChI=1S/C27H37N5O2S/c1-6-13-35(33,34)25-29-22(15-24(30-25)28-20-8-9-20)18-7-10-23-19(14-18)11-12-32(23)21-16-26(2,3)31-27(4,5)17-21/h7,10-12,14-15,20-21,31H,6,8-9,13,16-17H2,1-5H3,(H,28,29,30)
  • InChIKey:
  • NVS-CECR2-1: XVECNLUKQDKOST-UHFFFAOYSA-N
  • NVS-CECR2-C: MUEOODFBWCTDNL-UHFFFAOYSA-N
selectivity profile

Isothermal Titration Calorimetry

ITC measurements of the NVS-CECR2-1 with CECR2.

Temperature Shift Assay

Selectivity screening of chemical probe NVS-CECR2-1 determined by temperature shift assay. The temperature shifts were mapped onto the phylogenetic tree using red circles corresponding to ΔTm as indicated in the figure.

in vitro potency
cell based assay data

NanoBRET

Dose-dependent displacement of CECR2 from histone H3.3 following treatment with NVS-CECR2-1.

Fluorescence Recovery After Photobleaching

Half-times of fluorescence recovery (t1/2) after photo bleaching measured for CECR2 after treatment with NVS-CECR2-1 at different concentrations with or without SAHA.

pk properties
co-crystal structures
synthetic schemes
materials and methods

Isothermal Titration Calorimetry (ITC)

All calorimetric experiments were performed on a VP-ITC micro-calorimeter (MicroCalTM, LLC Northampton, MA). Protein solutions were buffer exchanged by gel filtration or dialysis into buffer (20 mM Hepes pH 7.5, 150 mM NaCl, and 0.5 mM tris (2-carboxyethyl) phosphine (TCEP). All measurements were carried out at 288.15 K. All injections were performed using an initial injection of 2 µL followed by injections of 8 µL. The data were analysed with the MicroCal ORIGIN software package employing a single binding site model. The first data point was excluded from the analysis. 

Temperature shift assay

Thermal melting experiments were carried out using a Stratagene Mx3005p Real Time PCR machine (Agilent Technologies). NVS-CECR2-1 was added at a final concentration of 10 µM. SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 1:1000 as described (6).

AlphaScreen Assay

Assays were performed as described previously with minor modifications (7). All reagents were diluted in 25 mM HEPES, 100 mM NaCl, 0.1 % BSA, pH 7.4 supplemented with 0.05 % CHAPS and allowed to equilibrate to room temperature prior to addition to plates. An 11-point 1:2.0 serial dilutions of the ligands was prepared on lowvolume 384-well plates (ProxiPlateTM-384 Plus, PerkinElmer, USA), using LabCyte Eco liquid handler. Plates filled with 5 µL of the assay buffer followed by 7 µL of peptide H4K5acK8acK12acK16ac. Plates were sealed and incubated for a further 30 minutes, before the addition of 8 µM of the mixture of streptavidin-coated donor beads (12.5 µg/mL) and nickel chelate acceptor beads (12.5 µg/mL) under low light conditions. Plates were foil-sealed to protect from light, incubated at room temperature for 60 minutes and read on a PHERAstar FS plate reader (BMG Labtech, Germany) using an AlphaScreen 680 excitation/570 emission filter set. IC50 values were calculated in Prism 5 (GraphPad Software, USA) after normalization against corresponding DMSO controls.

Fluorescence Recovery After Photobleaching (FRAP) Assay

FRAP studies were performed using U20S cells expressing full-length CECR2. Six hours after transfection 2.5 µM SAHA (to increase global histone acetylation) was added and cells were treated with 1 µM or 5 µM of NVS-CECR2-1 1 hour before imaging and half recovery times from the fluorescence signal of the bleached U2OS nuclei were plotted.

NanoBRET

U2OS cells were co-transfected with Histone H3.3-HaloTag and NanoLuc-CECR2. Twenty hours post-transfection cells were collected, washed with PBS, and exchanged into media containing phenol red-free DMEM and 4% FBS in the absence (control sample) or the presence (experimental sample) of 100 nM NanoBRET 618 fluorescent ligand (Promega). Cells were then treated with an increasing dose of NVS-CECR2-1. Five minutes prior to reading, NanoBRET furimazine substrate (Promega) was added to both control and experimental samples and plates were read on a CLARIOstar (BMG) equipped with 450/80 nm bandpass and 610 nm longpass filters with a 0.5 sec reading setting. A corrected BRET ratio was calculated and is defined as the ratio of the emission at 610 nm/450 nm for experimental samples (i.e. those treated with NanoBRET fluorescent ligand) subtracted by and the emission at 610 nm/450 nm for control samples (not treated with NanoBRET fluorescent ligand). BRET ratios are expressed as milliBRET units (mBU), where 1 mBU corresponds to the corrected BRET ratio multiplied by 1000. Relative IC50 values were estimated by non-linear regression analysis of (log) concentration of each inhibitor versus milliBRET ratios (GraphPad Prism).